EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Efficacy and Safety of Lebrikizumab in the Treatment of Atopic Dermatitis: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

Asia Batool, Muhammad Sharjeel Abbas, Saifullah Khan, Alisha Ahmad, Aiza Ahsan, Syeda Masooma Jafri, Makhzan Ali Akbar, Nabahat Shafi, Mrunalini Dandamudi, Prachi Gajjar C, Hasibullah Aminpoor, Evardo Barros de Deus Nunes Junior

Dermatologic Therapy · 2026-01 · 2026 (1)

DOI: 10.1155/dth/1905385 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Dermatologic Therapy, online erschienen am 30.05.2026. Verfasst von Asia Batool und 11 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Atopic dermatitis is a chronic inflammatory skin condition characterized by eczematous lesions and pruritus, which can significantly impair quality of life. Biologics have been introduced for the treatment; however, due to safety concerns, investigations for these systemic drugs continue. Lebrikizumab, a monoclonal antibody inhibiting IL‐13, not only reduces the immunological response but also minimizes the destructive effects of these cytokines on skin barriers. This meta‐analysis was conducted to assess the efficacy and safety profile of lebrikizumab in patients with atopic dermatitis.

Methods

A systematic review and meta‐analysis were conducted in accordance with the PRISMA guidelines. From conception until October 2025, literature was searched on PubMed, Embase, the Cochrane Library, and Scopus. Data were pooled from 4 studies comprising 1037 patients. Outcomes assessed include achievement of IGA (0.1) and ≥ 2‐point score from baseline to 16 weeks, EASI‐75 and EASI‐90 at 16 weeks, DLQI 4‐point improvement, DLQI, and reduction in sleep loss score and adverse events. Standardized mean differences (SMDs) or odds ratios (ORs) were calculated with 95% confidence intervals (CIs), and heterogeneity was examined using the I 2 statistic.

Results

Lebrikizumab was significantly superior to placebo in achieving IGA (0.1) (OR = 2.88; 95% CI: 1.73 to 4.79; p < 0.001) and EASI‐75 (OR = 2.98; 95% CI: 1.76 to 5.05; p < 0.001) at Week 16. It was also associated with DLQI 4‐point improvement (OR = 3.99; 95% CI: 1.51 to 10.56; p = 0.005), pruritus NRS ≥ 4‐point improvement (OR = 2.80; 95% CI: 1.56 to 5.04; p = 0.006), and DLQI (MD = −2.13; 95% CI: −3.55 to −0.71) from baseline to 16 weeks. Higher rates of treatment‐emergent adverse events (TEAEs) (OD = 1.42; 95% CI: 1.07 to 1.89; p = 0.02) and moderate AEs (OD = 1.53; 95% CI: 1.04 to 2.25; p = 0.03) were associated with lebrikizumab. The risk of serious adverse effects and infections was comparable across the two groups.

Conclusion

Lebrikizumab shows significant benefit in improving atopic dermatitis treatment by IGA (0.1), and ≥ 2‐point reduction, higher EASI‐75 response, and reduction in DLQI and pruritus score. However, lebrikizumab is associated with a higher risk of TEAS and moderate AEs.

Zitieren

APA

Batool, A., Abbas, M. S., Khan, S., Ahmad, A., Ahsan, A., Jafri, S. M., Akbar, M. A., Shafi, N., Dandamudi, M., C, P. G., Aminpoor, H., & Junior, E. B. D. D. N. (2026). Efficacy and Safety of Lebrikizumab in the Treatment of Atopic Dermatitis: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Dermatologic Therapy, 2026(1). https://doi.org/10.1155/dth/1905385

Vancouver

Batool A, Abbas MS, Khan S, Ahmad A, Ahsan A, Jafri SM, et al. Efficacy and Safety of Lebrikizumab in the Treatment of Atopic Dermatitis: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Dermatologic Therapy. 2026;2026(1). doi:10.1155/dth/1905385

BibTeX
@article{Batool2026,
  author = {Batool, Asia and Abbas, Muhammad Sharjeel and Khan, Saifullah and Ahmad, Alisha and Ahsan, Aiza and Jafri, Syeda Masooma and Akbar, Makhzan Ali and Shafi, Nabahat and Dandamudi, Mrunalini and C, Prachi Gajjar and Aminpoor, Hasibullah and Junior, Evardo Barros de Deus Nunes},
  title = {Efficacy and Safety of Lebrikizumab in the Treatment of Atopic Dermatitis: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials},
  journal = {Dermatologic Therapy},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/dth/1905385}
}
Kostenlos starten →